Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 11/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.42 |
| ▸ | IKZF2 | Q9UKS7 | 8/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.40 |
| ▸ | SALL4 | Q9UJQ4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30985154 | 0.82 | CRBN (0.45) | CRBNDDB1IKZF2CSNK1A1SALL4 | |
| SCHEMBL30984814 | 0.81 | CRBN (0.46) | CRBNDDB1IKZF2CSNK1A1SALL4 | |
| SCHEMBL30080844 | 0.81 | CRBN (0.43) | CRBNIKZF2CSNK1A1 | |
| SCHEMBL24880488 | 0.80 | CRBN (0.47) | CRBNIKZF2CSNK1A1 | |
| SCHEMBL31748857 | 0.80 | CRBN (0.53) | CRBNDDB1IKZF2CSNK1A1SALL4 | |
| SCHEMBL21759799 | 0.80 | CRBN (0.53) | CRBNDDB1IKZF2CSNK1A1SALL4 | |
| SCHEMBL20235032 | 0.79 | CRBN (0.49) | CRBNDDB1IKZF2CSNK1A1SALL4 | |
| SCHEMBL30906267 | 0.79 | CRBN (0.52) | CRBNDDB1IKZF2CSNK1A1SALL4 | |
| SCHEMBL20231475 | 0.79 | CRBN (0.52) | CRBNDDB1IKZF2CSNK1A1SALL4 | |
| SCHEMBL30080867 | 0.78 | CRBN (0.42) | CRBNDDB1IKZF2CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383908-A1 | SYNTHESIS AND APPLICATION OF PHOSPHATASE DEGRADER | HINOVA PHARMACEUTICALS INC. (CN) | 2024-11-21 | — | — | US | disclosed |
| CN-115594666-B | Synthesis and application of phosphatase degradation agent | 海创药业股份有限公司 | 2024-05-31 | — | — | CN | disclosed |
| EP-4368614-A1 | SYNTHESIS AND APPLICATION OF PHOSPHATASE DEGRADER | Hinova Pharmaceuticals Inc. (CN) | 2024-05-15 | — | — | EP | disclosed |
| CN-115594666-A | Synthesis and application of phosphatase degrading agent | 海创药业股份有限公司（CN） | 2023-01-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383908-A1 | SYNTHESIS AND APPLICATION OF PHOSPHATASE DEGRADER | DUSP1, PPM1D, PTPN1 | CRBN 576/4885DDB1 1687/4885IKZF2 1349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.